Community Practice Connections™: Improving Outcomes in Progressive Fibrosing-Interstitial Lung Disease (PF-ILD) Through Early and Accurate Diagnosis

Released On
June 30, 2019

Expires On
June 30, 2020

Media Type

Completion Time
60 minutes

Allergy & Immunology, Hospitalist, Pathology, Pulmonology, Radiology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Nursing Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is primarily directed towards radiologists. Pulmonologists, immunologists, pathologists, internists, specialty NPs, specialty PAs and additional healthcare practitioners interested in the diagnosis and management of PF-ILD will also be invited to participate.

Program Overview

Progressive fibrosing-interstitial lung disease (PF-ILD) comprises serious pulmonary disorders that have a significant impact on the quality of life of affected patients, with considerable morbidity and mortality. Diagnosis of PF-ILD is generally complicated because investigators have identified more than 100 forms of PF-ILD. Clinicians must be able to delineate the pathophysiologic mechanisms behind the various forms of PF-ILD and identify associated pathological fibrosis patterns to promote earlier diagnosis for prompt intervention. High-resolution computed tomography of the thorax can provide important information that strongly supports a more specific diagnosis and that suggests that invasive testing is not needed. With an ever-changing landscape for management of PF-ILDs, clinicians must be educated on all aspects of these disorders, including improvement of patient management and optimization of patient outcomes.

Benefits of Participating

  • Gain insights into the importance of early diagnosis and early highly efficacious treatment of PF-ILD to improve lung function and quality of life
  • Improve competence regarding the integration of novel and emerging therapies into the management of interstitial lung disease of a progressive phenotype
  • Increase awareness of the role of HRCT in the diagnosis and etiologic determination of ILD’s of a pressive fibrosing phenotype

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify key mechanisms underlying the various forms, clinical presentation, and management of PF-ILD
  • Interpret radiographic patterns on high-resolution computed tomography to differentially diagnose ILDs, including idiopathic pulmonary fibrosis
  • Improve ability to diagnose and differentiate PF-ILD earlier in its course to allow more prompt intervention
  • Discuss current and emerging treatments for management of the various forms of PF-ILD and their potential use in clinical practice


Joshua J. Solomon, MD

Associate Chief, Section of Critical Care
Associate Professor
Department of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO

Michael Kadoch, MD

Assistant Professor
Chief, Cardiothoracic Radiology
University of California, Davis
Sacramento, CA

Justin M. Oldham, MD, MS

Assistant Professor of Medicine
Director, Interstitial Lung Disease Program
University of California, Davis
Sacramento, CA

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Disclosures of Conflicts of Interest

Joshua J. Solomon, MD

  • Joshua J. Solomon, MD, has no financial relationships with commercial interest to disclose.

Michael Kadoch, MD

  • Speakers Bureau: Boehringer Ingelheim

Justin M. Oldham, MD, MS

  • Grant Research Support: National Institutes of Health, American College of Chest Physicians
  • Consultant: Boehringer Ingelheim, Genentech
  • Speakers Bureau: Boehringer Ingelheim, Genentech

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process